March 21, 2005
Prostate Cancer - Ferring's degarelix shows immediate onset of action and sustained activityTopics: Clinical Pharmacology
- Medical News Today
A dosing study with Degarelix, a novel gonadotrophin-releasing hormone (GnRH) receptor blocker, shows optimum efficacy in prostate cancer at higher doses.
XXth Congress of the European Association of Urologists (EAU), Istanbul, Turkey, March 19, 2005 ¨C The phase II dose-escalating study, presented for the first time today shows promising prospects for the use of Ferring's degarelix in the treatment of prostate cancer.
Based on these encouraging findings, degarelix is moving forward towards phase III clinical trials.
Posted by Hyscience at March 21, 2005 4:25 PM
Articles Related to Clinical Pharmacology:
- Prostate Cancer - Ferring's degarelix shows immediate onset of action and sustained activity - Mar 21, 2005